Virtual reality technology may be useful in such areas as exposure therapy and pain management.
The addition of intranasal ketamine, administered by paramedics, to usual treatment with nitrous oxide was found to alleviate acute pain and improve comfort within 30 minutes.
There is solid evidence supporting the notion that ketamine may have analgesic and antihyperalgesic properties.
In surgical patients, time to pain resolution, complete recovery from surgery, and opioid cessation were found to be predicted by the worst pain occurring 10 days after surgery.
The researchers identified 6 distinct trajectories for the resolution of acute pain after discharge from the emergency department.
An initial prescription of opioids for 4 to 7 days for the management of acute pain in the primary care setting was found to be sufficient.
The Food and Drug Administration (FDA) has sent a second Complete Response Letter to Recro Pharma concerning their New Drug Application for intravenous meloxicam.
An opioid supply for seven or fewer days might be sufficient for most patients seen in primary care settings for acute pain who appear to need opioid analgesics.
An authorized generic of Flector Patch (diclofenac epolamine topical patch) has been made available by Teva Pharmaceuticals for the topical treatment of acute pain due to minor strains, sprains, and contusions.
CL-108, a new combination of a low-dose antiemetic with hydrocodone and acetaminophen, may be a safe and effective prophylactic medication for the treatment of opioid-induced nausea and vomiting in individuals treated for moderate to severe acute pain.